Novartis Develops Advanced Medicines Using AI
Novartis partnered with Microsoft to integrate Microsoft's AI-powered solutions directly into their drug research processes in Basel, Switzerland. This collaboration enabled machine learning-driven capabilities to accelerate molecular design and focus on diseases like macular degeneration and development of gene therapies. The Novartis AI Innovation Lab has been integral to embedding AI solutions throughout their drug research pipeline, quickening design-test cycles.
- Organization
- Novartis
- Industry
- Healthcare
- Location
- Switzerland
- Published
- October 2019
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
- Customer
- Novartis
- Provider
- Microsoft
- Maturity
- Unknown
- Linked source
- swissinfo.ch
No explicit deployment-stage evidence found.
Primary read
Use case focus
Showing 2 of 2
- 1AI in molecular design
- 2Drug discovery platform transformation
- Established the Novartis AI Innovation Lab.
- Used machine learning and decision-support AI systems to accelerate molecular profiling.
- Optimized drug pathways integrating Microsoft computational AI.
- Cut molecular profiling time from years to months.
- Enhanced global operations in foundational drug research advancing life sciences.
Sources & evidence1
- Customer explicitly identified
- Recent evidence check available
- Last evidence check: Jul 22, 2026.
The same organization appears in newer AI deployment evidence.
- Same organization re-documented as recently as 2025.
- Cited source last checked Jun 12, 2026 — ok (0/1 broken).
Measures whether this deployment's public evidence persists — not whether the system is still in production.
AI-generated summary. Verify important details with the linked sources before relying on this case.
Explore related AI use cases
Was this useful?
Community
Comments
No published comments yet.